{
    "clinical_study": {
        "@rank": "57010", 
        "arm_group": [
            {
                "arm_group_label": "Algeron", 
                "arm_group_type": "Experimental", 
                "description": "Algeron at a dose of 1.5 \u00b5g/kg of body weight subcutaneously, once a week, and Rebetol, orally, at a daily dose of 800 mg (for body weight <65 kg), 1,000 mg (for body weight 65 - 85 kg), 1,200 mg (for body weight  86 - 105 kg) or 1,400 mg (for body weight  > 105 kg)."
            }, 
            {
                "arm_group_label": "Pegasys", 
                "arm_group_type": "Active Comparator", 
                "description": "Pegasys in a dose of 180 \u00b5g subcutaneously, once a week, in combination with Rebetol, orally, at a daily dose of 800 mg for patients with genotype 2 or 3, and for genotypes 1 or 4 at a daily dose of 1000 mg (for body weight <75 kg) or 1200 mg (for body weight \u226575 kg)"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study is to demonstrate the noninferiority of Algeron in combination with\n      ribavirin compared to Pegasys in combination with ribavirin in the treatment of chronic\n      hepatitis C."
        }, 
        "brief_title": "An Open-label Comparative Efficacy and Safety Study of Algeron (Cepeginterferon Alfa-2b) in Treatment-naive Patients With Chronic Hepatitis C", 
        "completion_date": {
            "#text": "November 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Hepatitis", 
            "Hepatitis C"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis, Chronic", 
                "Hepatitis C", 
                "Hepatitis C, Chronic"
            ]
        }, 
        "detailed_description": {
            "textblock": "The course of treatment in both groups shall be 12 weeks, and efficacy analysis, i.e. rate\n      of rapid (after the 4th week) and early (after the 12th week) virologic response will be\n      based on PCR data. For patients with treatment failure after the 12th week the antiviral\n      therapy shall be discontinued. All patients who require further anti-viral treatment will\n      receive a combination treatment with Algeron / Pegasys and ribavirin for another 12 or 36\n      weeks (depending on the HCV genotype). Sustained virologic response will be assessed 24\n      weeks after last dose of study treatment."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Signed informed consent to participate in the study.\n\n          2. Chronic HCV infection (genotypes 1\u0430, 1b, 2, 3, 4)  with detectable HCV RNA >6 month\n             before the screening visit or abnormal ALT levels for >6 month before the screening\n             visit.\n\n          3. Male and female patients, 18 to 70 years of age, inclusive.\n\n          4. Body mass index of 18 - 30 kg/m2.\n\n          5. Preserved protein synthetic liver function (INR < 1.7, albumin > 35 g/l).\n\n          6. No signs of hepatic encephalopathy or abdominal fluid retention according to clinical\n             and ultrasound examination.\n\n          7. Fertile patients and their partners agree to use barrier contraception throughout the\n             study treatment and 7 months after it.\n\n          8. Patient must have documentation of fibroscan within 1 year before the screening visit\n             or agree to have a fibroscan within the screening period.\n\n        Exclusion Criteria:\n\n          1. Intolerance to IFN alfa, ribavirin or any components of this preparations confirmed\n             by past medical history.\n\n          2. Infection by hepatitis B, A, E virus or HIV (co-infection).\n\n          3. Any other documented significant liver disease (drug or alcohol-related cirrhosis,\n             autoimmune hepatitis, hemochromatosis, Wilson's disease, nonalcoholic\n             steatohepatitis, biliary cirrohosis, etc.).\n\n          4. Past history of HCV treatment with IFN alfa or pegylated IFN alfa.\n\n          5. Administration of injectable and non-injectable interferons and/or some interferon\n             inducers for any indication (other than HCV) for one month before enrollment into the\n             study.\n\n          6. Cholestatic hepatitis (level of conjugated bilirubin, alkaline phosphatase, G-GTP\n             exceeding the upper normal level by more than 5 times).\n\n          7. Decompensated liver cirrhosis confirmed by laboratory findings (class B, \u0421 according\n             to Child-Pugh) or ultrasound examination.\n\n          8. Any documented autoimmune diseases (e.g., Crohn's disease, ulcerative colitis,\n             systemic lupus erythematosus, idiopathic thrombocytopenic purpura, scleroderma,\n             autoimmune haemolytic anemia, severe psoriasis).\n\n          9. Hemoglobin not lower than low normal level; neutrophils < 1.5 \u0445109/L; platelets < 90\n             \u0445109/L; creatinin level exceeding the upper normal level by more than 1.5 times, ALT\n             level exceeding the upper normal level by more than 10 times.\n\n         10. Documented hemoglobinopathies (e.g., thalassemia major, sickle-cell anemia).\n\n         11. Severe depression, schizophrenia, other mental disorders, which from the\n             investigator's point of view are a contraindication for anti-viral treatment.\n\n         12. Epilepsy and/or disorder of function of the central nervous system.\n\n         13. Abnormal thyroid function (TTH level beyond the normal values).\n\n         14. Diagnosed or suspected hepatocellular carcinoma as evidenced by screening\n             alfa-fetoprotein (AFP) of \u2265 upper normal level.\n\n         15. Antinuclear antibody (ANA) titer \u22651:640 at screening and/or evidence of autoimmune\n             hepatitis on liver biopsy.\n\n         16. Malignant neoplasms.\n\n         17. Pregnancy, lactation period.\n\n         18. Severe comorbidities (for example, severe hypertension, severe coronary heart\n             disease, decompensated diabetes mellitus) that represent a contraindication for\n             anti-viral treatment.\n\n         19. Documented rare hereditary diseases, such as intolerance of lactose, sucrose,\n             fructose, lactase deficiency or glucose-galactose malabsorption.\n\n         20. Known drug or alcohol abuse or signs of drug/alcohol abuse in present, which from the\n             investigator's point of view are a contraindication for anti-viral treatment or\n             restrict adherence to the treatment regimen.\n\n         21. Simultaneous participation in other clinical studies less than 30 days before\n             enrollment into this study or previous participation in this clinical study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "500", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01889433", 
            "org_study_id": "BCD-016-3"
        }, 
        "intervention": [
            {
                "arm_group_label": "Algeron", 
                "description": "1.5 \u00b5g/kg of body weight subcutaneously, once a week", 
                "intervention_name": "Algeron", 
                "intervention_type": "Drug", 
                "other_name": "Cepeginterferon alfa-2b"
            }, 
            {
                "arm_group_label": "Pegasys", 
                "description": "180 \u00b5g subcutaneously, once a week", 
                "intervention_name": "Pegasys", 
                "intervention_type": "Drug", 
                "other_name": "Peginterferon alfa-2a"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Peginterferon alfa-2a", 
                "Interferon-alpha"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Hepatitis C", 
            "Cepeginterferon alfa", 
            "Peginterferon", 
            "Treatment"
        ], 
        "lastchanged_date": "January 10, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Gomel", 
                        "country": "Belarus", 
                        "zip": "246029"
                    }, 
                    "name": "Gomel Regional Clinical Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vitebsk", 
                        "country": "Belarus", 
                        "zip": "210037"
                    }, 
                    "name": "Vitebsk Regional Clinical Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Porto Alegre", 
                        "country": "Brazil"
                    }, 
                    "name": "Hospital S\u00e3o Lucas - PUC Porto Alegre"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Indore", 
                        "country": "India", 
                        "zip": "452001"
                    }, 
                    "name": "Suyash Hospital Pvt. Ltd. Opposite M.G.M Medical College A.B. Road"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lucknow", 
                        "country": "India", 
                        "zip": "226003"
                    }, 
                    "name": "M V Hospital & Research Center"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mumbai", 
                        "country": "India", 
                        "zip": "400007"
                    }, 
                    "name": "Bhatia Hospital, Medical Research Society Tardeo Road, Grant Road (W)"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pune", 
                        "country": "India", 
                        "zip": "411007"
                    }, 
                    "name": "Medipoint Hospitals Pvt. Ltd."
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation", 
                        "zip": "127473"
                    }, 
                    "name": "State Budgetary Higher Vocational Education Institution A.I. Evdokimov Moscow State University of Medicine and Dentistry"
                }, 
                "status": "Enrolling by invitation"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation"
                    }, 
                    "name": "State Public Healthcare Institution of the City of Moscow \"Infectious Disease Clinical Hospital No. 1\""
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation"
                    }, 
                    "name": "State Budgetary Higher Vocational Education Institution I.M. Sechenov First Moscow State Medical University"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Samara", 
                        "country": "Russian Federation"
                    }, 
                    "name": "LLC Medical Company \"Hepatolog\""
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Saratov", 
                        "country": "Russian Federation"
                    }, 
                    "name": "Municipal Healthcare Institution City Clinical Hospital No.2 named after V.I. Razumovsky"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Smolensk", 
                        "country": "Russian Federation"
                    }, 
                    "name": "Smolensk Regional Clinical Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Smolensk", 
                        "country": "Russian Federation"
                    }, 
                    "name": "State Budgetary Higher Vocational Education Institution Smolensk State Medical Academy"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Petersburg", 
                        "country": "Russian Federation"
                    }, 
                    "name": "Federal State Military Higher Vocational Education Institution S.M. Kirov Military Medical Academy"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Petersburg", 
                        "country": "Russian Federation"
                    }, 
                    "name": "Federal State Budgetary Institution Research Institute of Influenza"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stavropol", 
                        "country": "Russian Federation"
                    }, 
                    "name": "State Budgetary Higher Vocational Education Institution Stavropol State Medical Academy"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tyumen", 
                        "country": "Russian Federation"
                    }, 
                    "name": "State Medical and Preventive Institution of the Tyumen Region \"Advisory and Diagnostic Center\""
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bangkok", 
                        "country": "Thailand", 
                        "zip": "10700"
                    }, 
                    "name": "Division of Gastroenterology, Department of Medicine, Faculty of Medicine, Siriraj Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chiang Mai", 
                        "country": "Thailand", 
                        "zip": "50200"
                    }, 
                    "name": "Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Maharaj Nakorn Chiang Mai Hospital"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Belarus", 
                "Brazil", 
                "India", 
                "Russian Federation", 
                "Thailand"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "An Open-label Randomized Multicenter Phase III Clinical Study Comparing Safety and Efficacy of Algeron (Cepeginterferon Alfa-2b) and Ribavirin With Pegasys (Peginterferon Alfa-2a) and Ribavirin for Treatment of Patients With Chronic Hepatitis C", 
        "other_outcome": {
            "description": "Proportion of randomized patients with neutralizing antibodies to IFN alfa", 
            "measure": "Immunogenicity", 
            "safety_issue": "Yes", 
            "time_frame": "Week 0, 12, 24, and additionally for patients with HCV 1, 4 genotype - week 48 after first administration of Algeron / Pegasys and 24 weeks after last dose of study treatment"
        }, 
        "overall_contact": {
            "last_name": "Andrey Biryulin, MD", 
            "phone": "(495) 992 66 28", 
            "phone_ext": "925"
        }, 
        "overall_contact_backup": {
            "email": "linkova@biocad.ru", 
            "last_name": "Yulia Linkova, PhD", 
            "phone": "(495) 992 66 28", 
            "phone_ext": "930"
        }, 
        "overall_official": [
            {
                "affiliation": "Federal State Military Higher Vocational Education Institution S.M. Kirov Military Medical Academy", 
                "last_name": "Konstantin Zhdanov, Professor", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "State Budgetary Higher Vocational Education Institution A.I. Evdokimov Moscow State University of Medicine and Dentistry", 
                "last_name": "Olga Znoyko, Professor", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "State Budgetary Higher Vocational Education Institution I.M. Sechenov First Moscow State Medical University", 
                "last_name": "Marina Maevskaya, Professor", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "LLC Medical Company \"Hepatolog\", Samara, Russia", 
                "last_name": "Vjacheslav Morozov", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Municipal Healthcare Institution City Clinical Hospital No.2 named after V.I. Razumovsky, Healthcare Committee at the Administration of \"Saratov City\" Municipal District", 
                "last_name": "Natalja Mironova, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "State Public Healthcare Institution of the City of Moscow \"Infectious Disease Clinical Hospital No. 1\", Moscow City Health Department", 
                "last_name": "Elena Nurmuhametova, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "State Budgetary Higher Vocational Education Institution Stavropol State Medical Academy, Ministry of Health of the Russian Federation", 
                "last_name": "Victor Pasechnikov, Professor", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "State Budgetary Higher Vocational Education Institution Smolensk State Medical Academy", 
                "last_name": "Natalia Petrochenkova, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Federal State Budgetary Institution Research Institute of Influenza, Ministry of Health of the Russian Federation, Saint-Petersburg", 
                "last_name": "Tamara Sologub, Professor", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Regional State Healthcare Institution \"Smolensk Regional Clinical Hospital\"", 
                "last_name": "Vladimir Rafalskiy, Professor", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "State Medical and Preventive Institution of the Tyumen Region \"Advisory and Diagnostic Center\", Tyumen", 
                "last_name": "Evgeniy Chesnokov, Professor", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "M V Hospital & Research Center, 314/30 Mirza Mandi, Chowk 226003, Lucknow 226003, Uttar Pradesh, India", 
                "last_name": "Sandeep Gupta, Dr", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Bhatia Hospital, Medical Research Society Tardeo Road, Grant Road (W), Maharashtra, India", 
                "last_name": "Tariq A Patil, Dr", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Medipoint Hospitals Pvt. Ltd. Maharashtra, India", 
                "last_name": "Mandar Doiphode, Dr", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Suyash Hospital Pvt. Ltd.  Opposite M.G.M Medical College A.B. Road, Madhya Pradesh, India", 
                "last_name": "G S Malpani, Dr", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Hospital S\u00e3o Lucas - PUC Porto Alegre, Avenida Ipiranga, 6.690, 2\u00ba andar - Bairro Jardim Bot\u00e2nico", 
                "last_name": "Maria Helena Sostruznik", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, Siriraj Hospital, Bangkoknoi, Bangkok, Thailand", 
                "last_name": "Tawesak Tanwandee", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Sriphum, Muang, Chiang Mai, Thailand", 
                "last_name": "Thongsawat Satawat", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Russia: Ministry of Health of the Russian Federation", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "November 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Proportion of randomized patients achieving early virologic response (EVR) - negative PCR result for HCV RNA (< 15 IU/ml) or \u2265 2log10 decrease of viral load after 12 weeks of study treatment", 
            "measure": "EVR", 
            "safety_issue": "Yes", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01889433"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Proportion of randomized patients achieving rapid virologic response (RVR) - negative PCR result for HCV RNA (< 15 IU/ml) after 4 weeks of treatment.", 
                "measure": "RVR", 
                "safety_issue": "Yes", 
                "time_frame": "4 weeks"
            }, 
            {
                "description": "Proportion of randomized patients achieving sustained virologic response (SVR) - negative PCR result for HCV RNA (< 15 IU/ml) 24 weeks after last dose of study treatment", 
                "measure": "SVR (24)", 
                "safety_issue": "Yes", 
                "time_frame": "24 weeks after last dose of study treatment"
            }, 
            {
                "description": "Proportion of randomized patients achieving end-of-treatment response (EOT) -undetectable HCV RNA (< 15 IU/ml) at the end of treatment (after 24 weeks of treatment for patients with genotype 2 or 3 and after 48 weeks of treatment for patients with genotype 1 or 4).", 
                "measure": "EOT", 
                "safety_issue": "Yes", 
                "time_frame": "After 24 weeks of treatment for patients with genotype 2 or 3 and after 48 weeks of treatment for patients with genotype 1 or 4"
            }, 
            {
                "description": "Proportion of patients who have ALT level \u2264 than upper normal level after 12 weeks of treatment, at the end of treatment (after 24 weeks of treatment for patients with genotype 2 or 3 and after 48 weeks of treatment for patients with genotype 1 or 4) and 24 weeks after last dose of study treatment.", 
                "measure": "Biochemical Response", 
                "safety_issue": "Yes", 
                "time_frame": "12, 24, 48 weeks of treatment, and 24 weeks after last dose of study treatment"
            }, 
            {
                "description": "Proportion of patients who have histological response, defined by a 1 level decrease in total METAVIR score measured on Fibroscan", 
                "measure": "Histological Response", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks of treatment and 24 weeks after last dose of study treatment"
            }
        ], 
        "source": "Biocad", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Biocad", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}